In the past fortnight, two vaccine stories made headlines around the world. Novavax announced spectacular results for its phase 3 trial, while preliminary data suggest the AstraZeneca vaccine is ineffective against the South African variant. These two vaccines comprise the bulk of Australia’s vaccine portfolio, and the results should prompt an urgent rethink of the country’s vaccination strategy. Australia […]
